A. Mark Fendrick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
A. Mark Fendrick has a total of 290 co-authors. Here are the top co-authors by number of shared publications:
- Michelle S. Rockwell
Department of Family & Community Medicine, Carilion Clinic and Virginia Tech Carilion School of Medicine, Roanoke, USA
27 shared publications - John N. Mafi
Division of General Internal Medicine & Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California
26 shared publications - Kyle B. Russell
Virginia Health Information, Richmond, Virginia
25 shared publications - Alison N. Huffstetler
Robert Graham Center for Primary Care Policy Studies, Washington, DC
24 shared publications - Jillian C. Capucao
Virginia Health Information, Richmond, Virginia
24 shared publications - John A. Rockwell
Department of Medicine, Carilion Clinic
24 shared publications
Latest Publications
- 30 October 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Hospital-level Variation in Medical Debt After Acute Traumatic Injury
Objective: To determine whether the treating hospital contributes to patients’ medical debt following injury. Summary Background Data: Trauma patients often have little or no choice in where they receive care. However, variation in hospital billing and collection practices, and their association with patient medical debt, remains poorly characterized. Methods: We conducted a retrospective cohort study of adult trauma patients hospitalized from January 2019 to December 2020 at 29 Level I and II trauma centers within a statewide quality collaborative. Trauma registry data were linked to quarterly consumer credit reports from 12 months preinjury through 18 months postinjury. The primary outcome was change in medical debt in collections from baseline to months 9–18 postinjury. Hierarchical mixed-effects models with empirical Bayes shrinkage and reliability adjustment estimated risk-adjusted hospital-level changes, adjusting for demographics, injury severity, and treatment intensity. Hospitals were classified as outliers if 95% confidence intervals for observed-minus-expected differences excluded zero. Results: Among 20,613 patients (mean age 63 y; 49% female; 82% non-Hispanic White), mean change in medical debt was $314 (SD $3464). Four hospitals (14%) were high outliers, generating $365–$566 more debt per patient than expected, while 4 (14%) were low outliers, generating $292–$676 less. Low-outlier hospitals cared for younger, lower-income, and higher-risk patients yet produced less debt than predicted. Findings were robust across sensitivity analyses. Conclusions: Substantial hospital-level variation in postinjury medical debt persists after adjustment for clinical and demographic factors. Billing, financial assistance, and collection practices may represent modifiable targets to reduce financial hardship after trauma.
- 30 October 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Hospital-level Variation in Medical Debt After Acute Traumatic Injury
Objective: To determine whether the treating hospital contributes to patients’ medical debt following injury. Summary Background Data: Trauma patients often have little or no choice in where they receive care. However, variation in hospital billing and collection practices, and their association with patient medical debt, remains poorly characterized. Methods: We conducted a retrospective cohort study of adult trauma patients hospitalized from January 2019 to December 2020 at 29 Level I and II trauma centers within a statewide quality collaborative. Trauma registry data were linked to quarterly consumer credit reports from 12 months preinjury through 18 months postinjury. The primary outcome was change in medical debt in collections from baseline to months 9–18 postinjury. Hierarchical mixed-effects models with empirical Bayes shrinkage and reliability adjustment estimated risk-adjusted hospital-level changes, adjusting for demographics, injury severity, and treatment intensity. Hospitals were classified as outliers if 95% confidence intervals for observed-minus-expected differences excluded zero. Results: Among 20,613 patients (mean age 63 y; 49% female; 82% non-Hispanic White), mean change in medical debt was $314 (SD $3464). Four hospitals (14%) were high outliers, generating $365–$566 more debt per patient than expected, while 4 (14%) were low outliers, generating $292–$676 less. Low-outlier hospitals cared for younger, lower-income, and higher-risk patients yet produced less debt than predicted. Findings were robust across sensitivity analyses. Conclusions: Substantial hospital-level variation in postinjury medical debt persists after adjustment for clinical and demographic factors. Billing, financial assistance, and collection practices may represent modifiable targets to reduce financial hardship after trauma.
- Open Access
- 23 September 2026
- Published by Springer Nature in BMC Health Services Research
Clinician-Level determinants of low-value acute back pain imaging in primary care
- 23 September 2026
- Published by Springer Nature in BMC Health Services Research
Open AccessClinician-Level determinants of low-value acute back pain imaging in primary care
- Open Access
- 17 July 2026
- Published by Elsevier in Obesity Pillars
- Vol. 19
A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management
- 17 July 2026
- Published by Elsevier in Obesity Pillars
- Vol. 19
Open AccessA survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management
- 1 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , 1061-1063
Optimizing the Uptake and Completion of the Cervical Cancer Screening Continuum: Opportunity Knocks, Including at Home
Despite decades of evidence demonstrating that cervical cancer screening prevents morbidity and mortality, approximately one in four eligible Americans remains overdue for screening. Screening gaps are unevenly distributed, disproportionately affecting uninsured individuals, those with lower income or educational attainment, rural residents, and racial and ethnic minority populations. In this commentary, we highlight that perceived out-of-pocket costs for cervical cancer screening—rather than actual costs—remain a salient and modifiable barrier to screening among low-income, underscreened women, even in the context of Affordable Care Act (ACA) provisions. Optimizing cervical cancer prevention requires attention not only to initial screening uptake but also to completion of the full screening continuum, including timely follow-up after abnormal results. Recent policy developments—including the US Supreme Court affirmation of the ACA preventive services mandate, elimination of cost-sharing for patient navigation beginning in 2026, expansion of coverage for diagnostic follow-up starting in 2027 for insured individuals, and endorsement of self-collected human papillomavirus testing—create an unprecedented opportunity to reduce financial and logistic barriers to completion of cervical cancer screening. However, realizing the population-level and equity benefits of these advances will require deliberate implementation strategies that emphasize transparent communication about patient out-of-pocket costs, integration of navigation services, and follow-up pathways. See related article by Isaacson et al., p. 1158
- 1 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , 1061-1063
Optimizing the Uptake and Completion of the Cervical Cancer Screening Continuum: Opportunity Knocks, Including at Home
Despite decades of evidence demonstrating that cervical cancer screening prevents morbidity and mortality, approximately one in four eligible Americans remains overdue for screening. Screening gaps are unevenly distributed, disproportionately affecting uninsured individuals, those with lower income or educational attainment, rural residents, and racial and ethnic minority populations. In this commentary, we highlight that perceived out-of-pocket costs for cervical cancer screening—rather than actual costs—remain a salient and modifiable barrier to screening among low-income, underscreened women, even in the context of Affordable Care Act (ACA) provisions. Optimizing cervical cancer prevention requires attention not only to initial screening uptake but also to completion of the full screening continuum, including timely follow-up after abnormal results. Recent policy developments—including the US Supreme Court affirmation of the ACA preventive services mandate, elimination of cost-sharing for patient navigation beginning in 2026, expansion of coverage for diagnostic follow-up starting in 2027 for insured individuals, and endorsement of self-collected human papillomavirus testing—create an unprecedented opportunity to reduce financial and logistic barriers to completion of cervical cancer screening. However, realizing the population-level and equity benefits of these advances will require deliberate implementation strategies that emphasize transparent communication about patient out-of-pocket costs, integration of navigation services, and follow-up pathways. See related article by Isaacson et al., p. 1158
- 18 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501241
Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non–Small Cell Lung Cancer: A Propensity Score–Weighted Analysis
PURPOSE: Pemetrexed remains part of guideline-recommended maintenance pemetrexed/pembrolizumab in advanced/metastatic non–oncogene-driven nonsquamous non–small cell lung cancer (NSCLC). Whether pemetrexed contributes to the combination's survival benefit is unknown. In this propensity-weighted analysis of US Veterans Affairs data, we compared real-world effectiveness and safety of maintenance pemetrexed/pembrolizumab versus maintenance pembrolizumab alone and estimated US government payer spending on maintenance pemetrexed. METHODS: We identified Veterans who received four cycles of carboplatin/cisplatin, pemetrexed, and pembrolizumab followed by at least one dose of maintenance pemetrexed/pembrolizumab or pembrolizumab. A propensity-weighted Cox model was used to adjust for baseline between-group differences using inverse probability of treatment weights. The primary effectiveness outcome was overall survival (OS; time from first maintenance dose to death). The primary financial outcome was the estimated spending on maintenance pemetrexed across VA, Medicare Part B, and Medicaid (2017-2022). RESULTS: The real-world outcomes cohort included 622 patients (473 pemetrexed/pembrolizumab; 149 pembrolizumab alone). After propensity weighting, pemetrexed was not associated with improved OS (adjusted hazard ratio [aHR] pemetrexed/pembrolizumab v pembrolizumab, 1.06 [95% CI, 0.83 to 1.36, P = .62]) but was associated with higher toxicity risk (grade ≥3 acute kidney injury [aHR 3.35, 95% CI, 1.08 to 10.41, P = .04]; neutropenia [aHR 2.86, 95% CI, 1.44 to 3.05; P = .004]; anemia [aHR 1.65, 95% CI, 1.11 to 2.47, P = .014]). Findings were robust to sensitivity analysis in which patients who crossed over from pembrolizumab to pemetrexed/pembrolizumab were excluded. Estimated government payer spending on maintenance pemetrexed from 2017 to 2022 totaled $1.588 billion (2024 USD). CONCLUSION: Adding pemetrexed to maintenance pembrolizumab was not associated with improved survival but was associated with increased toxicity. Reassessing legacy chemotherapy components may improve the safety and cost-effectiveness of cancer care . Prospective evaluation of maintenance pemetrexed's incremental benefit in NSCLC in the immunotherapy era is needed.
- 18 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501241
Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non–Small Cell Lung Cancer: A Propensity Score–Weighted Analysis
PURPOSE: Pemetrexed remains part of guideline-recommended maintenance pemetrexed/pembrolizumab in advanced/metastatic non–oncogene-driven nonsquamous non–small cell lung cancer (NSCLC). Whether pemetrexed contributes to the combination's survival benefit is unknown. In this propensity-weighted analysis of US Veterans Affairs data, we compared real-world effectiveness and safety of maintenance pemetrexed/pembrolizumab versus maintenance pembrolizumab alone and estimated US government payer spending on maintenance pemetrexed. METHODS: We identified Veterans who received four cycles of carboplatin/cisplatin, pemetrexed, and pembrolizumab followed by at least one dose of maintenance pemetrexed/pembrolizumab or pembrolizumab. A propensity-weighted Cox model was used to adjust for baseline between-group differences using inverse probability of treatment weights. The primary effectiveness outcome was overall survival (OS; time from first maintenance dose to death). The primary financial outcome was the estimated spending on maintenance pemetrexed across VA, Medicare Part B, and Medicaid (2017-2022). RESULTS: The real-world outcomes cohort included 622 patients (473 pemetrexed/pembrolizumab; 149 pembrolizumab alone). After propensity weighting, pemetrexed was not associated with improved OS (adjusted hazard ratio [aHR] pemetrexed/pembrolizumab v pembrolizumab, 1.06 [95% CI, 0.83 to 1.36, P = .62]) but was associated with higher toxicity risk (grade ≥3 acute kidney injury [aHR 3.35, 95% CI, 1.08 to 10.41, P = .04]; neutropenia [aHR 2.86, 95% CI, 1.44 to 3.05; P = .004]; anemia [aHR 1.65, 95% CI, 1.11 to 2.47, P = .014]). Findings were robust to sensitivity analysis in which patients who crossed over from pembrolizumab to pemetrexed/pembrolizumab were excluded. Estimated government payer spending on maintenance pemetrexed from 2017 to 2022 totaled $1.588 billion (2024 USD). CONCLUSION: Adding pemetrexed to maintenance pembrolizumab was not associated with improved survival but was associated with increased toxicity. Reassessing legacy chemotherapy components may improve the safety and cost-effectiveness of cancer care . Prospective evaluation of maintenance pemetrexed's incremental benefit in NSCLC in the immunotherapy era is needed.
- Open Access
- 20 March 2026
- Published by Elsevier in Gastro Hep Advances
- Vol. 5 (5)
Optimizing Colonoscopy Capacity to Maximize Colorectal Cancer Outcomes
- 20 March 2026
- Published by Elsevier in Gastro Hep Advances
- Vol. 5 (5)
Open AccessOptimizing Colonoscopy Capacity to Maximize Colorectal Cancer Outcomes
- 29 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (6) , 108289
Impact of Self-Reported Patient–Provider Communication on the Use of High- and Low-Value Care Among U.S. Adults
- 29 January 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 70 (6) , 108289
Impact of Self-Reported Patient–Provider Communication on the Use of High- and Low-Value Care Among U.S. Adults
- 21 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (2) , 69-72
Beyond No-Cost Screening: Ensuring Completion of the Colorectal Cancer Screening Continuum after Kennedy v. Braidwood
The 2025 Kennedy v. Braidwood Supreme Court decision upheld the Affordable Care Act mandate requiring insurance coverage of preventive services with an A/B rating from the U.S. Preventive Services Task Force (USPSTF) without cost-sharing. This ruling preserved access to essential preventive care, including colorectal cancer screening, a leading cause of cancer-related mortality despite the availability of effective, evidence-based screening methods. The recent elimination of out-of-pocket costs for follow-up colonoscopy after positive stool testing resulted in an absolute increase of 1.48% in follow-up procedures, highlighting the impact of financial barriers on the completion of the screening continuum. Yet nonfinancial barriers such as limited transportation, language barriers, and scheduling challenges persist. Patient navigation services addressing these barriers have demonstrated substantial improvements in screening adherence and diagnostic completion but remain inconsistently covered. Recent federal policies about breast and cervical cancer screening have expanded the definition of screening to include follow-up care and navigation services, now requiring coverage of these services by private insurers and Medicaid without cost-sharing. Colorectal cancer screening coverage should similarly expand to include these critical support services. Aligning policy with the realities of patient access will enhance screening uptake, reduce disparities, and strengthen the cost-effectiveness of colorectal cancer prevention efforts.
- 21 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (2) , 69-72
Beyond No-Cost Screening: Ensuring Completion of the Colorectal Cancer Screening Continuum after Kennedy v. Braidwood
The 2025 Kennedy v. Braidwood Supreme Court decision upheld the Affordable Care Act mandate requiring insurance coverage of preventive services with an A/B rating from the U.S. Preventive Services Task Force (USPSTF) without cost-sharing. This ruling preserved access to essential preventive care, including colorectal cancer screening, a leading cause of cancer-related mortality despite the availability of effective, evidence-based screening methods. The recent elimination of out-of-pocket costs for follow-up colonoscopy after positive stool testing resulted in an absolute increase of 1.48% in follow-up procedures, highlighting the impact of financial barriers on the completion of the screening continuum. Yet nonfinancial barriers such as limited transportation, language barriers, and scheduling challenges persist. Patient navigation services addressing these barriers have demonstrated substantial improvements in screening adherence and diagnostic completion but remain inconsistently covered. Recent federal policies about breast and cervical cancer screening have expanded the definition of screening to include follow-up care and navigation services, now requiring coverage of these services by private insurers and Medicaid without cost-sharing. Colorectal cancer screening coverage should similarly expand to include these critical support services. Aligning policy with the realities of patient access will enhance screening uptake, reduce disparities, and strengthen the cost-effectiveness of colorectal cancer prevention efforts.
- Open Access
- 20 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 41
Value of Stool-Based Colorectal Cancer Screening: Integrating Real-World Adherence, Detection, and Prevention in a Cohort-Based Modeling Analysis
Background/Objectives: Modeling analyses for colorectal cancer (CRC) screening focusing solely on the costs of screening do not fully capture the value of screening programs. We evaluated the clinical and economic effects of CRC stool-based screening tests, including impacts on cancer-related outcomes. Methods: A cohort-based decision-analytic cost-estimator model estimated outcomes for a single round of screening with next-generation multi-target stool DNA (ng mt-sDNA) test or fecal immunochemical test (FIT) from a US payer perspective. Undiagnosed cancers were assumed to become symptomatic (and detected) within 10 years. Clinical assumptions, advanced precancerous lesion and CRC prevalence, and test performance inputs were from clinical trial data. Adherence rates for initial screening and follow-up colonoscopy after a positive result were from real-world data. Input costs included the screening tests, follow-up colonoscopy (with and without polypectomy), and CRC treatment. Results: Compared with FIT, more individuals completed ng mt-sDNA (321,000 vs. 713,000, respectively), leading to the detection of more CRC cases (436 with FIT vs. 2235 with ng mt-sDNA), more advanced precancerous lesions, and more CRC at earlier stages. The cost of screening per patient screened was USD 801 for ng mt-sDNA and USD 124 for FIT. Follow-up colonoscopy cost was USD 149 million with ng mt-sDNA versus USD 22 million with FIT, whereas CRC treatment costs were lower for ng mt-sDNA (USD 1423 million versus USD 1474 million, respectively). When accounting for both direct and CRC averted costs, the total cost of screening and treatment was USD 1383 million with ng mt-sDNA versus USD 1427 million with FIT. Conclusions: Higher screening costs with ng mt-sDNA versus FIT are counterbalanced by savings realized from enhanced CRC prevention and earlier detection due to the superior test performance and better adherence with ng mt-sDNA.
- 20 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 41
Open AccessValue of Stool-Based Colorectal Cancer Screening: Integrating Real-World Adherence, Detection, and Prevention in a Cohort-Based Modeling Analysis
Background/Objectives: Modeling analyses for colorectal cancer (CRC) screening focusing solely on the costs of screening do not fully capture the value of screening programs. We evaluated the clinical and economic effects of CRC stool-based screening tests, including impacts on cancer-related outcomes. Methods: A cohort-based decision-analytic cost-estimator model estimated outcomes for a single round of screening with next-generation multi-target stool DNA (ng mt-sDNA) test or fecal immunochemical test (FIT) from a US payer perspective. Undiagnosed cancers were assumed to become symptomatic (and detected) within 10 years. Clinical assumptions, advanced precancerous lesion and CRC prevalence, and test performance inputs were from clinical trial data. Adherence rates for initial screening and follow-up colonoscopy after a positive result were from real-world data. Input costs included the screening tests, follow-up colonoscopy (with and without polypectomy), and CRC treatment. Results: Compared with FIT, more individuals completed ng mt-sDNA (321,000 vs. 713,000, respectively), leading to the detection of more CRC cases (436 with FIT vs. 2235 with ng mt-sDNA), more advanced precancerous lesions, and more CRC at earlier stages. The cost of screening per patient screened was USD 801 for ng mt-sDNA and USD 124 for FIT. Follow-up colonoscopy cost was USD 149 million with ng mt-sDNA versus USD 22 million with FIT, whereas CRC treatment costs were lower for ng mt-sDNA (USD 1423 million versus USD 1474 million, respectively). When accounting for both direct and CRC averted costs, the total cost of screening and treatment was USD 1383 million with ng mt-sDNA versus USD 1427 million with FIT. Conclusions: Higher screening costs with ng mt-sDNA versus FIT are counterbalanced by savings realized from enhanced CRC prevention and earlier detection due to the superior test performance and better adherence with ng mt-sDNA.